You are here

What’s the Stem Cells Buzz this Week? - CAR T Cell Therapies, Intestinal Stem Cell Fitness, Alveolar Injury treatment with EPCs, and iPSC Neuropsychiatric Disease Models!



The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!

Lessons Learned from CAR T cell Therapies for B Cell Malignancies

Soon to be approved chimeric antigen receptor T (CAR T) cell therapies for B cell malignancies in pediatric and adult patients represent a triumph of a true bench to bedside clinical translation. A new STEM CELLS article from Michael D. Jain and Marco L. Davila (H. Lee Moffitt Cancer Center and Research Institute, Florida, USA) aims to review the “lessons learned” from pre-clinical and human experience in this area. Sounds like a fascinating read!

Wnt-Signaling Pathway Regulates Intestinal Stem Cell Fitness

While multiple studies have demonstrated the importance of Wnt-signaling to intestinal stem cell (ISC) biology, the lab of Karen R Reed (Cardiff University, UK) decided to employ a more subtle approach in the hope of learning some of the intricacies. To this end, Young et al. prompted a minor misregulation of the Wnt-signaling pathway through the inhibition of the β-catenin regulator Apc2. Their new STEM CELLS paper describes how even a small change can significantly alter the function and fitness of ISCs.

EPCs Improve Alveolar Injury

Treatment of pre-term infants with high levels of oxygen (hyperoxia) can disrupt lung alveolar and vascular development; however, animal studies have suggested that endothelial progenitor cell (EPC) therapy may counter these problems. Now, researchers from the group of Alexandra B Firsova (Monash University) and Richard Mollard (University of Melbourne, Australia) have revealed that “fresh” bone-marrow-derived EPC-like cells can fully recover hyperoxia-induced alveolar disruption. Unfortunately, long-term in vitro culture of EPCs reduced therapeutic outcome and promoted unwanted growth. It seems that fresh is best for lung repair; check it out for yourself over at STEM CELLS Translational Medicine.

Reviewing iPSC Models for Neuropsychiatric Diseases

Underlying disease processes are generally unknown, and therapies lack efficacy; this is the unfortunate state of affairs for the sufferers of the major neuropsychiatric conditions of schizophrenia, affective disorders, and infantile autism. However, a new article from the lab of Anthony Wynshaw-Boris (Case Western Reserve University School of Medicine, Ohio, USA) now reviews how patient-derived induced pluripotent stem cell (iPSC) models and three-dimensional organoids with the capacity to differentiate into neurons and other neuronal cell lineages may lead to significant advances. See STEM CELLS Translational Medicine now for all the information on this fascinating area.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!